GlassScriptPhysician profile
Sanjeev Garg
NPI 1790728574
$47,180.13
in general payments reported to CMS, 2019-2025
54 companies · $6,614 in 2025
The $6,614 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,680 · 2020: $2,245 · 2021: $9,930 · 2022: $7,665 · 2023: $8,480 · 2024: $8,566 · 2025: $6,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $8,835 · Consulting Fee: $1,140 · Education: $144 · Travel and Lodging: $40.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $8,835.43 |
| Consulting Fee | $1,140.00 |
| Education | $144.13 |
| Travel and Lodging | $40.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,965.66 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,243.08 | 2019-2025 | |
| Genzyme Corporation | $1,666.15 | 2019-2022 | |
| Ucb, INC. | $1,520.10 | 2022-2025 | Zilbrysq, Nayzilam, Briviact |
| Alexion Pharmaceuticals, INC. | $1,104.35 | 2019-2025 | Ultomiris |
| Allergan, INC. | $1,086.77 | 2019-2021 | |
| Biogen, INC. | $1,071.62 | 2019-2025 | Vumerity, Plegridy, Tysabri |
| Teva Pharmaceuticals USA, INC. | $936.16 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $921.29 | 2019-2024 | Aimovig, Uplizna |
| Emd Serono, INC. | $915.31 | 2019-2025 | Mavenclad |
| Celgene Corporation | $794.61 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $686.99 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Amneal Pharmaceuticals LLC | $591.71 | 2019-2024 | Rytary, Ongentys 50mg Capsules 30, Ongentys |
| Eisai INC. | $561.26 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $476.07 | 2020-2022 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $440.39 | 2019-2022 | |
| Lundbeck LLC | $430.43 | 2022-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $409.85 | 2019-2021 | |
| Csl Behring | $375.79 | 2022-2024 | Hizentra |
| Neurelis, INC. | $366.80 | 2020-2025 | Valtoco |
| Mdd US Operations, LLC | $354.38 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Acadia Pharmaceuticals INC | $338.31 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $277.44 | 2020-2025 | Ingrezza, Ongentys |
| Avanir Pharmaceuticals, INC. | $245.69 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $218.05 | 2020-2021 | |
| Sk Life Science, INC. | $200.45 | 2020-2025 | |
| Argenx US, INC. | $188.36 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Astrazeneca Pharmaceuticals LP | $183.21 | 2023-2024 | |
| Tg Therapeutics, INC. | $181.84 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $178.61 | 2022 | |
| Sumitomo Pharma America, INC. | $177.93 | 2023-2024 | Aptiom |
| Impel Pharmaceuticals INC. | $175.69 | 2022-2023 | Trudhesa |
| Pfizer INC. | $171.36 | 2019-2024 | |
| Abbott Laboratories | $152.95 | 2021-2022 | |
| Kyowa Kirin, INC. | $148.75 | 2021-2024 | Nourianz |
| Axsome Therapeutics, INC. | $143.29 | 2023-2025 | Sunosi, Symbravo |
| Phathom Pharmaceuticals, INC. | $134.99 | 2025 | Voquezna |
| Catalyst Pharmaceuticals, INC. | $129.81 | 2021-2024 | Firdapse |
| Mallinckrodt Hospital Products INC. | $124.12 | 2020-2023 | Acthar |
| Tanabe Pharma America, INC. | $110.26 | 2021-2023 | |
| Adamas Pharmaceuticals, INC. | $108.59 | 2019 | |
| Genentech USA, INC. | $108.22 | 2020-2024 | Ocrevus, Enspryng |
| Otsuka America Pharmaceutical, INC. | $95.71 | 2023-2024 | Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $88.09 | 2020-2021 | |
| Horizon Therapeutics Plc | $81.23 | 2021-2023 | Uplizna |
| Avion Pharmaceuticals | $73.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $66.37 | 2024 | |
| Alnylam Pharmaceuticals INC. | $42.77 | 2024-2025 | Onpattro |
| Livanova USA, INC. | $30.45 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Cvrx, INC. | $22.48 | 2025 | Barostim Neo System |
| Ani Pharmaceuticals, INC. | $19.14 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.75 | 2024 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $13.66 | 2024 | Lumryz |
| Ge Healthcare | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.